Siglec-15:急性髓系白血病细胞表达的快速内化细胞表面抗原
该研究制备了特异性抗Siglec-15单克隆抗体A9E8,发现其可染色AML细胞系及患者CD33+原始细胞和CD34+白血病干细胞,而健康供者白细胞及非AML供者CD34+干细胞表达极低。A9E8结合后快速内化(半衰期180秒),提示Siglec-15抗体对AML治疗具有潜力。
要点
- Siglec-15在AML细胞和白血病干细胞高表达,健康细胞低表达
- A9E8抗体结合后快速内化,半衰期180秒
- Siglec-15可能成为AML靶向治疗新靶点
核心结论
- Siglec-15是AML细胞表达的快速内化表面抗原,抗体治疗潜力显著。
研究设计与样本
- 基础研究:利用噬菌体展示技术制备抗Siglec-15单克隆抗体A9E8,检测其染色及内化特性。
主要发现
- A9E8可染色AML细胞系及患者CD33+原始细胞和CD34+白血病干细胞。
- 健康供者白细胞及非AML供者CD34+干细胞上Siglec-15表达极低。
- A9E8结合后快速内化进入K562细胞,半衰期为180秒。
临床怎么用
- Siglec-15靶向抗体可能用于AML治疗,尤其针对白血病干细胞。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sialic acid-binding immunoglobulin-like lectin (Siglec)-15 has recently been identified as a critical tumour checkpoint, augmenting the expression and function of programmed death-ligand 1. We raised a monoclonal antibody, A9E8, specific for Siglec-15 using phage display. A9E8 stained myeloid leukaemia cell lines and peripheral cluster of differentiation (CD)33+ blasts and CD34+ leukaemia stem cells from patients with acute myeloid leukaemia (AML). By contrast, there was minimal expression on healthy donor leucocytes or CD34+ stem cells from non-AML donors, suggesting targeting Siglec-15 may have significant therapeutic advantages over its fellow Siglec CD33. After binding, A9E8 was rapidly internalised (half-life of 180 s) into K562 cells. Antibodies to Siglec-15 therefore hold therapeutic potential for AML treatment.
引用
- Cao H, Neerincx A, de Bono B, et al. Sialic acid-binding immunoglobulin-like lectin (Sigelac)-15 is a rapidly internalised cell-surface antigen expressed by acute myeloid leukaemia cells. Br J Haematol. 2021. PMID: 33951750. doi:10.1111/bjh.17496
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。